uniQure (QURE) - Rasio cepet

The current share price of uniQure N.V. (QURE), standing at 9.88 as shown on this chart, illustrates the price action of a gene therapy pioneer that corrects DNA defects using viral vectors. The business's success is based on licensing fees for hemophilia treatment and the outcomes of Huntington's disease trials. The company's development relies on fundamental scientific achievements, making its growth independent of economic cycles and macroeconomics.

For the long-term investor, the issuer's reliability is confirmed by its ability to instantaneously settle short-term debts without liquidating inventory, which is reflected in the current acid-test ratio of 9.88. This metric exclusively assesses "cash on hand" and accounts receivable, which is critically important for uniQure N.V. (QURE), as high-margin royalties from gene therapy convert directly into liquid assets and free cash flow.